What Is Mazdutide? The Science of a GLP-1 and Glucagon Dual Agonist
Mazdutide (initially designated LY3305677 by Eli Lilly and developed in partnership with Innovent Biologics under the name IBI362) is a novel once-weekly injectable peptide representing a major shift in metabolic pharmacology. While standard therapies like semaglutide operate as single GLP-1 receptor agonists and tirzepatide works as a dual GLP-1 and GIP agonist, mazdutide targets a different pathway by mimicking the endogenous human hormone oxyntomodulin. Oxyntomodulin is a naturally occurring peptide that acts as a dual agonist on both the glucagon receptor and the GLP-1 receptor. By activating these two complementary pathways simultaneously, mazdutide suppresses appetite while directly stimulating metabolic processes that increase energy expenditure. This mechanism offers a dual-action approach to weight loss and glycemic control, positioning it as a key molecule in the next generation of metabolic therapies.
How Glucagon Agonism Changes the Metabolic Equation
The addition of glucagon receptor agonism is what fundamentally separates mazdutide from single-receptor GLP-1 therapies. In traditional GLP-1 protocols, weight reduction is driven primarily through central appetite suppression and slowed gastric emptying, which reduces caloric intake. However, these mechanisms do not typically increase resting energy expenditure or target hepatic lipid buildup directly. Glucagon receptor activation addresses this by stimulating hepatic gluconeogenesis, enhancing brown adipose tissue thermogenesis, and promoting lipolysis in the liver. This means that while the GLP-1 component helps patients consume fewer calories, the glucagon component active in mazdutide works to burn more energy at a cellular level and clear fat from liver tissue. This dual-action pathway makes the peptide highly relevant for metabolic dysfunction-associated steatotic liver disease, or MASLD, alongside obesity.
| Medication | Receptor Targets | Primary Mechanism | Metabolic Focus |
|---|---|---|---|
| Semaglutide | GLP-1 Receptor (Single Agonist) | Appetite suppression and delayed gastric emptying | Caloric restriction and glycemic control |
| Tirzepatide | GLP-1 and GIP Receptors (Co-Agonist) | Satiety signaling paired with adipose lipid buffering | Enhanced weight loss and insulin sensitivity |
| Mazdutide | GLP-1 and Glucagon Receptors (Co-Agonist) | Satiety combined with hepatic thermogenesis and lipid oxidation | Weight loss, calorie burning, and liver fat reduction |
Protocol Optimization and Clinical Monitoring
Clinical trials such as the Phase 3 GLORY-1 study have demonstrated that activating both the GLP-1 and glucagon pathways produces significant reductions in body weight alongside improvements in lipid profiles. As patients explore next-generation therapies, understanding the full spectrum of GLP-1 benefits and metabolic side effects becomes critical. For those on active regimens, miora is a weight-loss and peptide companion that lives in iMessage. It captures daily logs conversationally (30 seconds), surfaces pattern signals before titration decisions, and lets users carry structured tracking into prescriber visits. Unlike basic tracker apps or telehealth-only providers, miora adds a clinician in the loop to review current peptide stacks and oversee clinical data, providing a specialized level of guidance. To ensure patients maintain safety and therapeutic efficacy throughout their cycle, learning how to track peptide cycles with structured clinical oversight is essential for long-term success. For those interested in optimizing their metabolic health, visiting the landing page at https://concierge.getmiora.com/ provides a detailed look at custom coaching resources.
Who Makes Mazdutide? The Eli Lilly and Innovent Partnership
Mazdutide was originally designed and synthesized by Eli Lilly and Company under the development code name LY3305677, also historically known in early-stage literature as OXM3. As a long-acting synthetic analog of the mammalian peptide oxyntomodulin, the molecule is engineered to activate both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This dual pathway differs fundamentally from single-receptor GLP-1 agonists like semaglutide, as it combines glycemic control with the metabolic rate-increasing effects of glucagon.
In August 2019, Eli Lilly entered into an exclusive licensing agreement with Chinese biopharmaceutical company Innovent Biologics for the development and potential commercialization of the compound within China. Under this multi-year partnership, Innovent assumed the responsibility and clinical execution for trials in Greater China, where their rapid trial progression has outpaced Western development. However, Eli Lilly retains all global development and marketing rights for the United States, Europe, and all other markets outside of China.
Licensing and Regional Rights Breakdown
| Entity | Role | Geographic Territory Rights |
|---|---|---|
| Eli Lilly and Company | Original Developer and Patent Holder | Global (excluding China, including United States and Europe) |
| Innovent Biologics | Exclusive Licensee for Clinical Dev & Commercialization | Greater China |
For individuals following modern peptide protocols, understanding the development lineage of dual-agonist molecules like mazdutide is critical. Because glucagon receptor activation introduces a different side-effect profile (including metabolic, cardiac, and thermogenic changes) compared to pure GLP-1 therapies, patients must monitor their response closely. To manage these complex, multi-receptor protocols, clinical companions can help track daily variables.
miora is a weight-loss and peptide companion that lives in iMessage. It captures daily logs conversationally (30 seconds), surfaces pattern signals before titration decisions, and lets users carry structured tracking into prescriber visits. The platform adds a clinician in the loop to review current peptide stacks, which serves as a critical safety differentiator compared to basic tracking apps. This clinician-supported layer is highly useful for individuals tracking next-gen protocols, similar to the multi-pathway mechanics observed in retatrutide weight loss models, helping patients optimize their health data through the new landing page at https://concierge.getmiora.com/ while navigating novel clinical-stage compounds.
Mazdutide Clinical Trials: Key Weight Loss and Metabolic Data
The clinical development of once-weekly mazdutide, developed by Innovent Biologics under license from Eli Lilly, reached a significant milestone with the readout of its Phase 3 GLORY-2 clinical trial (NCT06164873). This 60-week double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of a high-dose 9 mg regimen of mazdutide combined with lifestyle intervention. The study cohort comprised 462 Chinese adults with a body mass index of 30 kg/m2 or higher, representing individuals with moderate-to-severe obesity, including 16% of participants who also had type 2 diabetes. The mean baseline body weight of the participants was 94.0 kg, establishing a rigorous clinical framework to assess the therapeutic limits of this dual receptor agonist.
The primary weight loss results demonstrated robust efficacy, with the mazdutide 9 mg group maintaining continuous, non-plateauing weight loss through the end of the 60-week treatment period. In the overall cohort, participants receiving the active drug achieved a mean body weight reduction of 18.55%, compared to a 3.02% reduction in the placebo group. The therapeutic impact was even more pronounced among individuals without type 2 diabetes, who experienced an average weight reduction of 20.08% at week 60, with nearly half of these participants (48.7%) achieving a total weight loss of 20% or more of their baseline body weight.
| Endpoint (60 Weeks) | Mazdutide 9 mg (Active Group) | Placebo Group | Statistical Significance |
|---|---|---|---|
| Mean Weight Loss (Overall) | 18.55% | 3.02% | P < 0.0001 |
| Mean Weight Loss (Without T2D) | 20.08% | 2.81% | P < 0.0001 |
| Participants Achieving >=20% Weight Loss (Without T2D) | 48.7% | 3.1% | P < 0.0001 |
| Liver Fat Content Reduction (Baseline >=10%) | -71.9% | 5.1% (Increase) | P < 0.0001 |
Glucagon-Mediated Metabolic and Liver Fat Benefits
What distinguishes mazdutide from single-receptor GLP-1 therapies is its dual activation of the glucagon receptor. While the GLP-1 component suppresses appetite and delays gastric emptying, glucagon receptor agonism increases energy expenditure and directly targets lipid metabolism in the liver. In a subset of GLORY-2 trial participants without type 2 diabetes who entered the study with a baseline liver fat content of 10% or higher, MRI-PDFF measurements revealed a 71.9% reduction in liver fat by week 60, compared to a 5.1% increase in the placebo group. This exceptional clearing of hepatic lipids mirrors the metabolic profiles observed in other advanced co-agonists such as retatrutide. Furthermore, the trial met all key secondary endpoints, showing significant improvements in waist circumference, systolic blood pressure, triglycerides, LDL cholesterol, and serum uric acid levels.
Tolerability, Safety, and Clinical Tracking Protocols
In terms of clinical safety, once-weekly administration of mazdutide 9 mg demonstrated a highly favorable tolerability profile. Gastrointestinal adverse events, which are common to all incretin-based therapies, were primarily mild to moderate in severity and transient. Discontinuations due to adverse events occurred in only 2.9% of the mazdutide 9 mg group, while the placebo group recorded no discontinuations. To manage potential gastrointestinal issues and maintain treatment compliance, understanding which peptide side effects to monitor is essential for anyone on a high-efficacy regimen.
Because metabolic changes and side-effect profiles shift throughout a therapy cycle, patients benefit from clinical systems designed to log peptide symptoms on a consistent basis. This is where the health assistant miora fits into a modern lifestyle. It functions as a weight-loss and peptide companion that lives in iMessage, capturing daily logs conversationally in 30 seconds, surfacing pattern signals before titration decisions, and preparing users to carry structured tracking into prescriber visits. To provide comprehensive clinical support, adds a clinician in the loop to review current peptide stacks and progress. This active clinician layer is the primary differentiator compared to standard tracker apps and virtual telehealth providers, giving users a higher standard of safety and guidance.
When Will Mazdutide Arrive in the US? Projected FDA Timeline
The global development of mazdutide (formerly known as LY3305677) has proceeded on two distinct geographical tracks. In China, Innovent Biologics has driven the peptide through rapid clinical development, culminating in regulatory approval by China’s National Medical Products Administration (NMPA) in June 2025 for chronic weight management. This regulatory milestone was supported by the GLORY-1 phase 3 trial, which demonstrated substantial weight loss and metabolic improvements in Chinese cohorts. However, patients looking to access the dual GLP-1 and glucagon receptor agonist in the United States must navigate a different regulatory timeline.
In the US, Eli Lilly retains the development rights for mazdutide and is advancing the therapeutic candidate under its own domestic trial schedules. Mazdutide remains in Phase 2 clinical trials in the US, focusing on establishing optimal dose-response curves and safety profiles in Western populations. Because the FDA requires large, multi-year Phase 3 trial programs to confirm both glycemic control efficacy and long-term cardiovascular safety, an FDA filing and subsequent US market launch is projected for 2028 or 2029. This timeline reflects the standard multi-year duration needed to design, recruit, and execute large-scale trials across diverse US demographics.
| Milestone | China (NMPA Pathway) | United States (FDA Pathway) |
|---|---|---|
| Phase 2 Status | Completed in 2023 | Completed or Ongoing |
| Phase 3 Program | Completed (GLORY trials) | Projected to launch in 2026 |
| Regulatory Approval | Approved in June 2025 | Projected for 2028 or 2029 |
| Market Distribution | Commercialized | Pending clinical trials and FDA review |
While US patients wait for new multi-receptor peptides like mazdutide to clear local regulatory hurdles, maintaining consistency on existing protocols is paramount. For those currently navigating active therapies, utilizing systematic tools to manage a peptide injection schedule can help keep titration plans on track. Additionally, choosing from the best peptide tracker apps provides structured data to share during clinician consultations. Developing a highly disciplined approach to dosing frequency, hydration levels, and physiological feedback loops remains the safest and most effective way to optimize clinical outcomes while waiting for pipelines to mature.
To fill the gap between self-tracking and clinical oversight, miora serves as a weight-loss and peptide companion that lives in iMessage. The platform captures daily logs conversationally in just 30 seconds, surfaces pattern signals before titration decisions, and lets users carry structured tracking into prescriber visits. Unlike automated tools or telehealth-only programs, miora differentiates itself by putting a clinician in the loop to review current peptide stacks and metabolic metrics. This clinician layer is the key differentiator versus other tracker apps and telehealth-only providers. Users can explore membership options and start tracking on the new landing page at https://concierge.getmiora.com/ to gain complete visibility into their protocol data.
Mazdutide vs. Retatrutide: Lilly’s Next-Generation Weight Loss Pipeline
As the therapeutic landscape for metabolic disorders shifts, Eli Lilly is advancing a highly strategic dual-track pipeline. At the forefront of this next generation are two molecules: retatrutide and mazdutide. While the triple receptor agonist is drawing substantial interest in US clinical trials for its raw weight reduction potency, mazdutide represents a highly targeted dual-agonist alternative. For those seeking to understand what is mazdutide GLP-1, it is a compound that pairs GLP-1 receptor activation with direct glucagon receptor stimulation. This unique combination shifts the clinical focus from sheer fat reduction to an optimized metabolic and liver-clearing profile.
Mechanistic Differences: Dual vs. Triple Receptor Agonism
The operational difference between these two molecules lies in their receptor targeting. Retatrutide targets three separate pathways: GLP-1, GIP, and glucagon. This triple-receptor activation maximizes insulin sensitivity and appetite suppression, leading to unprecedented weight loss outcomes in trials. Conversely, mazdutide is a dual agonist targeting only the GLP-1 and glucagon receptors. By omitting GIP, mazdutide isolates the therapeutic synergy of glucagon and GLP-1. Glucagon acts as a metabolic accelerator by increasing energy expenditure and directly promoting lipid oxidation in the liver. This mechanism is highly attractive for individuals focusing on muscle preservation because it targets metabolic rate and energy balance through alternative endocrine pathways.
| Metric | Mazdutide (LY3305677) | Retatrutide (LY3437943) |
|---|---|---|
| Receptor Targets | GLP-1 and Glucagon | GLP-1, GIP, and Glucagon |
| Primary Metabolic Focus | Liver fat clearance and lipid oxidation | Maximum glycemic control and adipose reduction |
| Pivotal Clinical Programs | GLORY-1 and GLORY-2 trials | TRIUMPH-1 and TRIUMPH-2 trials |
| Peak Trial Weight Loss | 18.55% weight reduction at 60 weeks (9 mg dose)[[cite:https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=564]] | 28.3% weight reduction at 80 weeks (12 mg dose)[[cite:https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html]] |
Liver-Clearing and Metabolic Profiling
While retatrutide currently leads in raw weight reduction percentage, mazdutide excels in its targeted metabolic and liver-clearing profile. By stimulating the glucagon receptor, mazdutide increases lipid metabolism inside the hepatocytes of the liver. Data from the Phase 3 GLORY-1 study demonstrated that mazdutide not only induced robust weight loss in adults with obesity but also significantly reduced liver fat content and improved overall cardiovascular and lipid metabolic biomarkers. This makes it an especially promising candidate for patients with metabolic dysfunction-associated steatotic liver disease, formerly known as NAFLD, who require liver clearance alongside weight management.
Navigating these advanced therapeutic choices requires precise, objective tracking. For individuals undergoing next-generation peptide protocols, miora is a weight-loss and peptide companion that lives in iMessage. It captures daily logs conversationally (30 seconds), surfaces pattern signals before titration decisions, and lets users carry structured tracking into prescriber visits. The clinician-in-the-loop layer reviews current peptide stacks, providing a personalized level of clinical oversight that generic tracking apps lack. Combining this conversational helper with a dedicated peptide tracker helps patient protocols stay highly organized, particularly as complex compounds like mazdutide and retatrutide transition from trials to clinical use.
Navigating Next-Gen Peptides: Managing Your Protocol Today
As next-generation dual agonists like mazdutide proceed through pivotal clinical trials, managing active therapy protocols becomes more complex. In phase 3 trials such as GLORY-1 and GLORY-2, mazdutide has demonstrated substantial efficacy, with high-dose regimens achieving up to 20% weight reduction at week 60. However, the physiological combination of GLP-1 and glucagon receptor agonism requires meticulous tracking of metabolic markers, heart rate, and gastrointestinal symptoms. For patients undergoing complex peptide protocols, the ability to track peptide cycles is a critical component of safety and long-term efficacy, helping individuals understand how their bodies adapt to multi-receptor stimulation.
This level of scrutiny is particularly important when evaluating potential peptide side effects like transient nausea, injection-site reactions, or changes in resting heart rate. Introducing next-generation peptides requires a patient-centered approach to titration rather than relying on generic dosing schedules. Because these therapies act on multiple endocrine pathways simultaneously, patients must monitor their daily tolerability. Understanding how to map your individual GLP-1 nausea curves helps users identify biological levers and determine whether symptoms are stabilizing before committing to a higher dose.
Why Clinician-in-the-Loop Tracking Matters
For active users of these regimens, miora is a weight-loss and peptide companion that lives in iMessage. It captures daily logs conversationally in about 30 seconds, surfaces pattern signals before titration decisions, and lets users carry structured tracking into prescriber visits. Rather than relying on simple automated reminders, the miora Protocol provides continuous daily tracking, wearable integration with devices like WHOOP or Oura, and a clinical concierge layer. This clinical layer allows a clinician to actively review current peptide stacks and side-effect histories, serving as a key differentiator compared to standard tracking apps or telehealth-only providers that offer limited post-prescription support.
| Protocol Aspect | Standard App Tracking | miora Protocol |
|---|---|---|
| Data Capture | Manual typing in fragmented screens | Conversational iMessage logging in 30 seconds |
| Biometric Integration | Disconnected raw charts | Wearable data synthesized with symptom logs |
| Clinical Oversight | None or basic automated triage | Clinician in the loop reviewing peptide stacks |
| Prescriber Alignment | Unstructured memory | Structured tracking files for doctor visits |
By synthesizing wearable biometrics with daily symptom logging, patients can approach their titration decisions with concrete data. This objective history reduces the guesswork often associated with multi-agonist therapies, ensuring that any adjustments are grounded in clinical tolerance. Ultimately, having a clinician-supported tracking protocol allows users to safely navigate the therapeutic transition from standard GLP-1 molecules to the highly potent, multi-receptor peptides of the future.
